Advertisement
Advertisement
AKBA
Akebia Therapeutics, Inc.
0.91
USDSponsored
-0.04
-4.66%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.91
0.00
+0.12%
AKBA Earnings Reports
Positive Surprise Ratio
AKBA beat 19 of 43 last estimates.
44%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$54.17M
/-$0.04
Implied change from Q2 26 (Revenue/ EPS)
+10.27%
/+100.00%
Implied change from Q3 25 (Revenue/ EPS)
-7.81%
/--
Akebia Therapeutics, Inc. earnings per share and revenue
On Aug 05, 2026, AKBA reported earnings of -0.02 USD per share (EPS) for Q2 26, beating the estimate of -0.04 USD, resulting in a 55.46% surprise. Revenue reached 49.13 million, compared to an expected 49.84 million, with a -1.42% difference. The market reacted with a -26.02% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 54.17 million USD, implying an increase of 100.00% EPS, and increase of 10.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Akebia Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Akebia Therapeutics, Inc. reported EPS of -$0.02, beating estimates by 55.46%, and revenue of $49.13M, -1.42% below expectations.
How did the market react to Akebia Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -26.02%, changed from $1.29 before the earnings release to $0.95 the day after.
When is Akebia Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Akebia Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.04 and revenue of $54.17M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement